<DOC>
	<DOCNO>NCT00398957</DOCNO>
	<brief_summary>The primary objective study examine OROSÂ® Hydromorphone HCL pharmacokinetic ( way drug enters leave blood tissue time ) profile dose proportionality administration 8mg , 16mg , 32mg 64 mg tablet .</brief_summary>
	<brief_title>An Open-Label Evaluation Dose Proportionality OROS� Hydromorphone HCL Tablets 8mg , 16mg , 32mg , 64mg</brief_title>
	<detailed_description>This randomize ( patient assign different treatment base chance ) , open-label , four-way crossover study perform normal , healthy adult patient . Each patient receive follow orally administer treatment OROS® Hydromorphone HCL ( different treatment dose phase ) : Treatment A : 8mg ; Treatment B : 16mg ; Treatment C : 32mg ; Treatment D : 64mg ; A naltrexone 50mg dose administer 12 hour prior , time , 12 study drug administration ; Patients receive fourth dose naltrexone 50mg 24 hour 64mg study drug administration . There 7-day washout period study drug dose phases.Venous blood sample time 0 ( prior dosing ) , 2 , 4 , 6 , 8 , 10 , 12 , 16 , 20 , 24 , 30 , 36 , 42 , 48 hour study drug administration . Three additional blood sample ( 56 , 64 , 72 hour dose study drug ) drawn patient receive 64 mg tablet ; LC/MS/MS ( Liquid Chromatography/Mass Spectroscopy/Mass Spectroscopy ) techniques employ analysis plasma hydromorphone concentrations.The primary endpoint interest : Area concentration-time curve zero infinity ; Area concentration-time curve zero time ; Peak plasma concentration ; secondary endpoint parameter : Time peak plasma concentration ; Terminal half-life . OROS hydromorphone HCL tablets 8mg , 16mg , 32mg , 64mg give orally , different dose treatment dose phase . One naltrexone HCL 50mg tablet give orally 12 hour prior , time , 12 hour hydromorphone administration dose phase . Patient receive fourth dose naltrexone 50mg 24 hour follow 64mg study drug administration ; It four week treatment seven-day washout period dose phase .</detailed_description>
	<mesh_term>Hydromorphone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Narcotic Antagonists</mesh_term>
	<criteria>Patients nonsmoking , healthy volunteer body weight 135 220 pound within +/ 10 % recommend weight range height body frame accord Metropolitan Height Weight Tables Patients negative baseline urine screen drug abuse Patients clinically significant deviation normal laboratory test value . Patients intolerant hypersensitive hydromorphone naltrexone Patient gastrointestinal disorder may affect absorption orally administer drug Patients depress respiratory function Patient impair renal hepatic function Patient dependence opiates pregnant breast feed Female patient child bear potential must negative pregnancy test week prior administration study drug require follow medically rhydromorphoneadministrationnaltrexone recognize contraceptive program prior study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Analgesia</keyword>
</DOC>